Research Study

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis
Principal Investigator 
Robert Carruthers

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT03523858
Status 
Recruiting
Study Start/End 
Feb 28, 2020 to Sep 30, 2023
Locations 
UBC Hospital
Name/Title 
Camille Hunt, Research Coordinator
Phone 
604-827-1892
Email Address 
camille.hunt@ubc.ca
Purpose of Study 

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.